Complement Autoantibody Assay

Q: Can you distinguish binding autoantibodies from functionally active autoantibodies?

Yes. Binding assays such as ELISA or multiplex immunoassays can identify target reactivity, while functional assays evaluate whether the detected autoantibodies affect complement activity. Creative Biolabs can combine both assay types to help clients determine biological relevance.

Q: What sample type is best for complement autoantibody testing?

The optimal sample type depends on the intended assay. Serum is often preferred for functional complement assays. EDTA plasma may be acceptable for binding-only assays but is generally not suitable for complement activation readouts. Citrate plasma can be used in selected workflows with appropriate controls. Purified IgG can be useful for confirming antibody-mediated function.

Q: Can complement autoantibody testing be combined with C3b deposition or CH50/AH50 assays?

Absolutely. Many projects benefit from a cascade-level testing strategy. Complement autoantibody detection can be paired with C3b deposition, C5b-9 deposition, CH50, AH50, C3a, C5a, sC5b-9, and individual component activity assays to better understand pathway consequences.

Q: Can you develop a custom assay for a new complement autoantibody target?

Yes. Creative Biolabs supports custom assay development for novel or less common complement autoantibody targets. We can help evaluate antigen format, detection reagents, assay conditions, controls, and feasibility before scaling to larger sample sets.

Q: How many samples can you process?

Creative Biolabs supports small pilot studies, medium-scale research projects, and larger cohort testing. Throughput depends on assay format, number of targets, sample matrix, replication requirements, and whether functional testing is included.

Q: What will I receive at the end of the project?

Clients typically receive a final report including study design, assay methods, sample information, raw and processed data, figures, QC summaries, observations, and interpretation. Additional deliverables such as plate maps, flow cytometry files, statistical summaries, or assay transfer documents can be provided upon request.

Creative Biolabs provides comprehensive complement autoantibody test services. Our complement autoantibody testing solutions are designed to detect, quantify, and functionally interpret autoantibodies directed against complement proteins, regulatory factors, convertase complexes, and pathway-associated targets. We can design a testing workflow aligned with your scientific question, sample type, target pathway, and development stage.

Submit Your Request Now

Download our service brochure

Inquiry

The Role of Complement Autoantibodies in Complement Activity

Complement autoantibodies are increasingly recognized as important contributors to disease heterogeneity. In some settings, they act as direct pathogenic drivers. In others, they serve as biomarkers that indicate immune dysregulation, pathway bias, disease activity, or therapeutic responsiveness. Autoantibodies may target individual complement components, such as C1q, C3, C4, Factor B, Factor H, Factor I, C5, or properdin. They may also recognize neoepitopes exposed during activation, bind assembled convertases, or interact with complement-regulatory domains in a way that changes functional activity.

Key questions addressed by complement autoantibody testing include:

Does a patient-derived or experimental sample contain autoantibodies against a defined complement component?
Are the detected antibodies merely binding events, or do they alter pathway activity?
Do autoantibodies stabilize C3 or C5 convertases and prolong complement activation?
Do they block regulatory proteins such as Factor H, Factor I, C1 inhibitor, CD46, CD55, or CD59?
Are autoantibody levels associated with complement activation products, hemolytic activity, tissue deposition, or disease phenotype?
Can complement autoantibody testing support biomarker selection, patient stratification, or therapeutic mechanism-of-action studies?

Creative Biolabs addresses these questions through integrated assay design.

Great Minds Choose Creative Biolabs

Partner with Us

What We Test

Creative Biolabs offers flexible complement autoantibody testing panels covering classical pathway, lectin pathway, alternative pathway, terminal pathway, and complement regulatory targets. Depending on the project objective, testing may be configured as a targeted single-analyte assay, a focused disease-associated panel, or a broader exploratory screen.

Anti-Factor H Autoantibodies

Anti-Factor H antibody testing is especially valuable in studies of acquired complement dysregulation, renal complement disorders, and alternative pathway-mediated pathology. Creative Biolabs can evaluate anti-Factor H autoantibodies using antigen-binding assays, domain-specific mapping strategies, competition assays, and optional functional readouts.

C3 Nephritic Factor and Convertase-Stabilizing Autoantibodies

Rather than simply detecting binding to a single purified antigen, C3 nephritic factor testing often requires functional assay design that evaluates convertase persistence, C3 consumption, C3 fragment generation, or pathway-specific amplification. Creative Biolabs supports C3 nephritic factor testing using customized approaches.

C4 Nephritic Factor and Classical/Lectin Convertase Autoantibodies

C4 nephritic factor-like activity may stabilize classical or lectin pathway C3 convertase complexes, thereby prolonging complement activation through C4b2a-mediated mechanisms. Creative Biolabs can design assays to examine classical or lectin pathway convertase stabilization, C4 and C3 consumption, pathway-specific deposition, and complement activation product generation.

C5 Nephritic Factor and Terminal Pathway-Linked Autoantibodies

Creative Biolabs can evaluate C5 convertase-related autoantibody activity using functional complement readouts, C5a quantification, sC5b-9 measurement, hemolysis-based assays, and pathway-specific activation models. These tests can be combined with C3 convertase assays to determine whether autoantibody effects are primarily upstream, terminal, or cascade-spanning.

Anti-C1q Autoantibodies

Creative Biolabs provides anti-C1q antibody detection and quantification assays using optimized antigen presentation, serum or plasma sample handling, positive and negative controls, and optional correlation with classical pathway activity, C4d generation, C3b deposition, or immune complex binding.

Autoantibodies Against Complement Components

In addition to major regulatory targets, Creative Biolabs can develop assays for autoantibodies against individual complement components, including C3, C3b, C3d, C4, C4b, Factor B, Factor D, properdin, C5, C6, C7, C8, C9, MASP proteins, MBL-associated targets, and pathway-specific complexes.

Autoantibodies Against Complement Regulators

Creative Biolabs supports testing for autoantibodies against soluble and membrane-associated regulators, including Factor H, Factor I, C1 inhibitor, C4b-binding protein, CD46, CD55, CD59, and other project-specific targets.

Discuss Your Needs

Assay Formats Available at Creative Biolabs

Complement autoantibody testing often requires multiple assay layers. A binding assay may confirm that an antibody recognizes a complement target, while a functional assay determines whether the antibody activates, blocks, stabilizes, or dysregulates the cascade. Creative Biolabs offers both standard and customized assay formats to match the biological question.

ELISA-Based Autoantibody Detection

A robust and scalable format for detecting autoantibodies

Multiplex Complement Autoantibody Panels

Design multiplex panels using bead-based, array-based, or other compatible detection platforms

Functional Complement Autoantibody Assays

Functional assays are essential when autoantibodies are suspected to alter complement activity

Cell-Based Complement Autoantibody Assays

Build cell-based assays using customized cell models

Our Typical Workflow

Creative Biolabs develops complement autoantibody testing workflows according to project goals, sample availability, target specificity, and required level of interpretation. A typical project may include the following stages.

Workflow	Descriptions
Project Consultation and Assay Strategy	Our scientists discuss the client's research question, suspected autoantibody target, disease context, sample type, species, cohort size, available controls, and desired readouts. We then recommend a testing strategy that may include binding assays, functional assays, confirmatory assays, or integrated complement panels.
Assay Feasibility and Design	For established targets, Creative Biolabs can proceed with optimized platforms. For custom targets, we evaluate antigen source, antigen format, epitope preservation, detection reagents, matrix compatibility, and control availability.
Sample Receipt and Quality Review	Client samples are received, logged, and inspected according to agreed requirements. We document sample condition, volume, labeling, storage temperature, freeze-thaw status when provided, and any deviations that may affect interpretation.
Binding Autoantibody Detection	Samples are tested for target-specific autoantibody binding using ELISA, chemiluminescent, fluorescent, multiplex, or customized immunoassay formats.
Functional Characterization	When functional relevance is required, positive or selected samples can be evaluated in pathway-specific complement assays.
Data Analysis and Interpretation	Creative Biolabs provides processed data, figures, QC summaries, and interpretive comments. Where appropriate, results are normalized to controls, reference samples, calibrators, or baseline activity. We can also provide recommendations for follow-up testing.
Final Report and Project Discussion	At closeout, clients receive a comprehensive report including study design, materials, methods, assay conditions, raw and processed results, figures, QC outcomes, limitations, and scientific interpretation.

Design Your Workflow

Sample Requirements

Serum or Plasma

Preferred matrix for many complement functional assays
Fresh frozen samples are recommended
Avoid repeated freeze-thaw cycles
Provide collection, processing, storage, and clinical or experimental metadata when available

Cell Samples

Cell type, passage number, culture conditions, viability, and surface marker information should be provided
Fresh cells are preferred for cell-surface complement activation studies
Cryopreserved cells may be acceptable after feasibility assessment

Purified IgG

Useful for confirming antibody-mediated effects
Recommended concentration: project-dependent
Buffer composition should be provided
Low-endotoxin preparations may be preferred for cell-based assays

Recombinant Antibodies or Candidate Molecules

Provide concentration, formulation buffer, species, isotype, subclass, Fc engineering information, and purity data when available
Aggregation status may influence complement-related assays and should be documented when known

Add-On Assays That Sharpen Interpretation

Complement autoantibody results often become more informative when integrated with additional complement readouts. Creative Biolabs offers a broad set of complementary assays that can be added to complement autoantibody testing projects.

Add-On Assays	Descriptions
Complement Activity Tests	CH50 total classical pathway activity AH50 alternative pathway activity Lectin pathway activity Individual component functional tests C1q, C2, C3, C4, C5, Factor B, Factor D, Factor H, Factor I, and properdin-related assays
Complement Activation Product Tests	C3a quantification C5a quantification Ba and Bb measurement C4d detection iC3b/C3d analysis sC5b-9 quantification C3b deposition assay C5b-9 deposition assay
Cell-Based Functional Assays	Complement-dependent cytotoxicity assay Cell-surface C3b deposition MAC deposition analysis Flow cytometry-based opsonization assay Endothelial or epithelial cell complement activation models Immune complex-mediated complement activation assays
Mechanistic Add-Ons	Antigen domain mapping Antibody isotyping and subclass analysis IgG purification and re-testing Convertase stabilization assays Regulator binding inhibition Pathway-specific blocking studies Complement inhibitor rescue experiments

Design Your Customization

Case Studies

Case 1

Anti-FH titers and their functional characterization

Of 781 patients <18-year-old of aHUS in the nationwide database from 2007 to 2018, 436 (55.8%) had anti-FH antibodies. In plasma samples of 44 aHUS patients, levels of serial circulating FH immune complexes (CIC), free FH, soluble terminal complement complex (sC5b-9), sheep red blood cell (SRBC) lysis and epitope specificity were examined.

Anti-factor H antibody associated atypical hemolytic uremic syndrome. (OA Literature) Fig. 1 Anti-FH titers remained detectable during remission.^1,2

References

Puraswani, Mamta, et al. "Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database." Frontiers in Immunology 10 (2019): 1282. https://doi.org/10.3389/fimmu.2019.01282
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

"The most helpful part of working with Creative Biolabs was the clarity of the final report. In addition to raw and processed data, they included QC notes, assay limitations, and interpretation of the complement pathway readouts. This made it much easier for our internal team to make decisions about follow-up experiments."

— Director of Preclinical Research, Complement Therapeutics Company

"We needed more than a standard CH50 or AH50 readout. Creative Biolabs combined hemolysis, C3b deposition, C5a, and sC5b-9 analysis to build a functional inhibition story around our candidate. The results clarified where our molecule acted in the complement cascade."

— Principal Investigator, Academic Immunology Laboratory

"Our initial goal was to screen for complement autoantibodies, but Creative Biolabs recommended adding functional assays to determine whether the binding signals had real pathway-level effects. That turned out to be critical for our project. The final report helped us distinguish target reactivity from complement-modulating activity."

— Senior Scientist, Immunology Research Group

"We were investigating suspected alternative pathway dysregulation in a small but complex serum sample set. Creative Biolabs helped us design a testing workflow that included anti-Factor H antibody detection, pathway-specific controls, and follow-up functional readouts. The team clearly understood the challenges of complement-sensitive samples and provided data that helped us prioritize the most biologically relevant cases."

— Translational Research Scientist, Academic Medical Center

Frequently Asked Questions

Can you distinguish binding autoantibodies from functionally active autoantibodies?

Yes. Binding assays such as ELISA or multiplex immunoassays can identify target reactivity, while functional assays evaluate whether the detected autoantibodies affect complement activity. Creative Biolabs can combine both assay types to help clients determine biological relevance.

What sample type is best for complement autoantibody testing?

The optimal sample type depends on the intended assay. Serum is often preferred for functional complement assays. EDTA plasma may be acceptable for binding-only assays but is generally not suitable for complement activation readouts. Citrate plasma can be used in selected workflows with appropriate controls. Purified IgG can be useful for confirming antibody-mediated function.

Can complement autoantibody testing be combined with C3b deposition or CH50/AH50 assays?

Absolutely. Many projects benefit from a cascade-level testing strategy. Complement autoantibody detection can be paired with C3b deposition, C5b-9 deposition, CH50, AH50, C3a, C5a, sC5b-9, and individual component activity assays to better understand pathway consequences.

Can you develop a custom assay for a new complement autoantibody target?

Yes. Creative Biolabs supports custom assay development for novel or less common complement autoantibody targets. We can help evaluate antigen format, detection reagents, assay conditions, controls, and feasibility before scaling to larger sample sets.

How many samples can you process?

Creative Biolabs supports small pilot studies, medium-scale research projects, and larger cohort testing. Throughput depends on assay format, number of targets, sample matrix, replication requirements, and whether functional testing is included.

What will I receive at the end of the project?

Clients typically receive a final report including study design, assay methods, sample information, raw and processed data, figures, QC summaries, observations, and interpretation. Additional deliverables such as plate maps, flow cytometry files, statistical summaries, or assay transfer documents can be provided upon request.